Angimax

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Angimax

Quick Facts

Property Description
Active ingredient Trimetazidine dihydrochloride
Form Modified-release tablets (MR tablets)
Pharmacological class Metabolic modulator, Cytoprotective anti-ischemic agent
Common use Adjunct therapy for the symptomatic treatment of stable angina
Origin Synthetic piperazine derivative

What Type of Antianginal Medicine is Angimax?

Angimax is a synthetic single-ingredient product featuring Trimetazidine dihydrochloride as its active constituent, chemically defined as a piperazine derivative. It is classified as an antianginal agent and a unique metabolic modulator. Angimax is supplied primarily as Modified-release tablets (MR tablets) intended for oral administration, providing sustained delivery of the active substance. The use of the drug is specifically restricted to an add-on therapy for the symptomatic treatment of stable angina pectoris when first-line options are insufficient or not tolerated. This means the drug serves as a complementary support when standard heart treatments are not fully effective.

How Does Trimetazidine Dihydrochloride Work in Principle?

The mechanism of Trimetazidine focuses on making the heart muscle’s energy production more efficient, acting as a cytoprotective anti-ischemic agent. It works by partially inhibiting fatty acid β-oxidation (FAO), which prompts the myocardial cells to utilize the more oxygen-efficient glucose oxidation as their primary fuel source. This cellular anti-ischemic effect is crucial for maintaining essential intracellular ATP levels. By optimizing energy metabolism, Trimetazidine directly improves the protection of heart cells during periods of reduced blood flow. The primary function of this approach is to enhance the heart muscle's resilience and capacity to perform effectively even under conditions of relative oxygen deprivation.

What Distinguishes Angimax from Other Heart Medications?

Angimax is intended as an adjunct therapy and is fundamentally different from traditional antianginal agents, such as β-blockers or calcium antagonists, because its function is non-hemodynamic. Its unique focus on metabolic efficiency—rather than regulating blood pressure or heart rate—is a key differentiating factor. This characteristic allows the drug to provide a complementary therapeutic strategy by directly addressing the energy deficit within heart cells, which is why it is often chosen when patients require a support mechanism that avoids further hemodynamic alteration.

Regulatory References

  1. Trimetazidine EPAR Summary
  2. Trimetazidine EMA Review

What side effects are possible with Angimax?

Possible Side Effects and Safety Information

The safety profile for Angimax (trimetazidine dihydrochloride) is structured by official regulatory bodies based on the frequency and the organ system affected by adverse reactions. This information is derived from clinical studies and post-marketing surveillance.


Official Adverse Reaction Listings

Official documents classify side effects into specific frequency categories:

  • Common Reactions (ge 1/100 to < 1/10): These include adverse effects related to the Gastrointestinal System (e.g., nausea, vomiting, abdominal pain) and the Nervous System (headache, dizziness). Asthenia (weakness) is also commonly reported.
  • Uncommon Reactions (ge 1/1,000 to < 1/100): These often involve the Vascular System, such as orthostatic hypotension and flushing, as well as Skin Disorders (rash, pruritus).

Serious and Specific Safety Concerns

The regulatory label documents the potential for rare but significant adverse reactions, particularly affecting the nervous and blood systems:

  • Movement Disorders: The emergence or worsening of Parkinsonian symptoms (e.g., tremor, akinesia, gait instability) is an officially listed concern. These symptoms are generally documented as reversible upon the discontinuation of the medicine.
  • Hematological and Hepatic Events: Rare but serious reactions such as agranulocytosis (a severe drop in white blood cells) and hepatitis have been documented in official post-marketing reports.

Population-Specific Constraints

Safety limitations are defined for certain patient groups:

  • Absolute Contraindications: The medicine is strictly contraindicated in individuals with confirmed Parkinson’s disease and in those with severe renal impairment (creatinine clearance < 30 mL/min).
  • Specific Caution: Caution is noted for older adults and patients with moderate renal impairment as increased drug exposure may occur in these populations.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents provide specific details regarding the manifestations and required emergency actions for an Angimax (trimetazidine dihydrochloride) overdose.

Feature Documented Regulatory Statement
Documented Manifestations Symptoms reported in overdose cases include hypotension (low blood pressure), flushing, and tachycardia (rapid heart rate).
Physiological Effect Overdose can lead to pronounced vasodilation that drives resulting severe arterial hypotension, which may be associated with symptoms like malaise or dizziness.
Antidote Status No specific antidote is known. Treatment is mandated to be strictly symptomatic and supportive.

Required Emergency Actions and Monitoring

  • If more than the recommended dose is taken, patients are directed to seek medical advice immediately.
  • It is required to contact your doctor or the nearest hospital Emergency Department immediately.

The severity of the cardiovascular effects, particularly the pronounced hypotension, dictates the need for urgent procedural steps. Official guidance states that hospitalisation for continuous observation and management of cardiovascular parameters may be required in severe cases. The official overdose profile is limited to these documented clinical signs, required emergency actions, and necessary procedural monitoring.

Therapeutic Uses of Angimax

What Angimax Treats: Main Uses and Benefits

Angimax may be part of symptomatic management for stable angina pectoris, a chronic heart condition. It is generally used to help manage symptoms related to this condition, primarily the recurring chest discomfort or pressure often triggered by physical effort. The therapeutic benefit may contribute to easing the overall symptom load and supports managing the frequency and intensity of these episodes.

The medication is specifically indicated as an add-on therapy for patients whose symptoms are not adequately controlled by or who are intolerant to other conventional treatments. This use assists with easing the chronic symptom burden and may help reduce the patient's reliance on symptomatic relief measures. This complementary approach is particularly relevant for those seeking support in managing recurrent symptoms, functional limitations, and effort-induced chest pain.

Supporting the patient’s functional capacity and exercise tolerance is a therapeutic goal. This support may contribute to easing symptoms that interfere with daily functioning and supports general well-being during symptomatic phases.


Quick Fact: Symptomatic Support for Chronic Angina
Primary Use: Symptomatic Management of Stable Angina Pectoris
Use Context: Adjunct therapy (Add-on)
Main Symptoms Addressed: Anginal chest discomfort and episode frequency

Eligibility and Restrictions for Use

Who Can and Cannot Use Angimax?

Angimax (Trimetazidine dihydrochloride) eligibility is strictly defined by regulatory authorities and centers on age, organ function, and pre-existing neurological conditions.

Contraindications (Must Not Use)

The medicine is absolutely contraindicated for patients with:

  • Known hypersensitivity to the active substance or any excipient.
  • Parkinson disease, parkinsonian symptoms, tremors, restless leg syndrome, or other related movement disorders.
  • Severe renal impairment (creatinine clearance less than 30 ml/min).

Population and Condition Restrictions

Population Group Regulatory Status
Pediatric Population (under 18 years) Not recommended; safety and efficacy are not established.
Elderly Patients (over 75 years) Use requires caution and monitoring due to potential reduced renal function.
Moderate Renal Impairment (CrCl 30-60 ml/min) Use requires caution and a reduced dose.
Pregnancy Preferable to avoid due to insufficient data.
Breastfeeding Should not be used.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Angimax (Trimetazidine dihydrochloride) is defined by the findings of clinical studies regarding co-administration with other medicinal products and substances. This profile is characterized by a high degree of specificity in the absence of documented interactions.

Official Interaction Status

Category Officially Documented Status/Entity
Documented Drug–Drug Interactions None identified in regulatory clinical studies.
Documented Food Interactions No interactions with foodstuffs have been found to influence the drug's characteristics.
Interaction-Related Restrictions No mandatory timing or co-administration prohibitions are documented based on drug-drug interactions.

Population-Specific Exposure Alteration

Official prescribing information notes an alteration in the drug's pharmacokinetics based on patient physiology, rather than co-administered substances. An increased exposure of the active substance is expected in two specific patient populations due to age or reduced organ function. This includes patients with moderate renal impairment (creatinine clearance between 30 and 60 ml/min) and elderly patients who are older than 75 years of age.

Connection to the Overall Interaction Profile

Regulatory documents establish that the interaction structure of Trimetazidine is fundamentally characterized by the explicit absence of identified interactions with co-administered medicines and common foodstuffs. Consequently, the official labeling does not contain specific warnings or timing-based restrictions for co-administration. The only documented constraint involves the drug’s concentration being higher in vulnerable populations due to physiological changes, which is a population-dependent pharmacokinetic finding noted in the official regulatory documentation.

Mechanism of Action

The mechanism of Angimax (Trimetazidine dihydrochloride) is defined by its precise, non-hemodynamic action as a metabolic modulator that influences cellular stability.

️ Targeted Inhibition of Fatty Acid Oxidation

Angimax works by acting as a selective partial inhibitor of the mitochondrial enzyme Long-Chain 3-Ketoacyl Coenzyme A Thiolase (LC 3-KAT), thereby reducing the flux of the Fatty Acid beta-Oxidation (FAO) pathway. This targeted inhibition, by reducing FAO flux, redirects the myocardial cell to prioritize the Glucose Oxidation pathway as its primary energy source.

️ Modulating Cellular Energy Efficiency

The stimulation of glucose oxidation results in a higher ATP yield per unit of oxygen consumed (increased O2 efficiency). This sustained energy supply supports the function of cell membrane ion pumps, contributing to the preservation of the heart cell’s internal ionic balance by modulating the accumulation of Na^+ and Ca^2+ and limiting the development of lactic acidosis. This preservation of ionic homeostasis allows the cardiac tissue to preserve its contractile capacity during metabolic stress.

Dosage and Administration Information

Angimax is administered exclusively via the oral route using a Modified-Release tablet. The medicine is generally used as part of a long-term strategy and is not intended for the acute management of an angina episode.

The standard administration schedule for adults is one 35 mg tablet taken twice daily, resulting in a 70 mg total daily dose. To ensure proper sustained delivery, the tablet must be swallowed whole and should not be crushed, broken, or chewed. Each dose should be taken during a meal, once in the morning and once in the evening. If a dose is missed, it should not be compensated for by taking a double dose; the patient must simply resume the normal regimen.

Treatment duration is conditional upon the patient's response. The drug's benefit is re-assessed after a three-month period, and continuation of the treatment is contingent upon a demonstrated positive response.

Specific high-level dose adjustments are defined for certain patient groups. For individuals with moderate renal impairment (creatinine clearance 30-60 mL/min), the dose is reduced to one 35 mg tablet taken once daily. In older adults (over 75 years), caution should guide dosing due to potential age-related decline in kidney function. Use in the pediatric population (below 18 years) is not supported by efficacy and safety data and is therefore not recommended.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Angimax

Evidence for Use in Stable Angina Pectoris

This section will summarize the core evidence from randomized controlled trials (RCTs) and comprehensive meta-analyses that examined the use of Angimax as an add-on therapy for the symptomatic management of stable angina pectoris. The summary focuses on the types of outcomes measured in these clinical studies.

In these short-term clinical trials, research examined how the frequency of anginal episodes changed over time. Studies monitored the reported number of weekly angina attacks within the observed populations. Research also monitored the patients' reliance on short-acting nitrate medication. Some studies reported measurements of how nitrate medication consumption evolved during the study period.

Examination of Functional and Symptom Outcomes

Studies monitored physiological strain by measuring changes during standardized physical stress tests. Researchers examined outcomes related to functional imbalance by recording the total amount of time patients could exercise on a treadmill or stationary bicycle before symptoms or signs of heart strain began. Studies monitored the time until patients reached specific endpoints of symptoms and physiological indicators during these exercise tests. Studies also examined patient-reported outcomes describing perceived discomfort, focusing on effects on daily functioning and activity level.

Long-Term Research and Major Clinical Events

The majority of highly controlled trials that observed changes in symptoms and functional capacity were conducted over relatively short periods, typically lasting a few weeks or months. The research volume and duration focusing on short-term symptom changes is greater than the data available for long-term outcomes. Studies monitored the occurrence of long-term events, such as cardiac death or hospitalization for heart failure, and their association with the medicine.

What Is Still Uncertain About Angimax Research

Evidence highlights what is known—and what is still uncertain. The primary focus of the available research has been on temporary or episodic changes in symptoms rather than on the long-term effects on the underlying disease progression. Long-term effects are not fully established, as follow-up durations were limited in many initial key studies. Research explored outcomes related to physical functional measures, however, the evidence base is limited regarding the association between these short-term functional changes and long-term major adverse cardiac events. Research is ongoing to address these open questions.

Key Studies & References Trimetazidine as Adjunctive Therapy for Decreasing Major Adverse Cardiac Events in Coronary Artery Disease Patients (Meta-Analysis, 2022)

Frequently Asked Questions (FAQ)

Common questions about Angimax (FAQ)


Q: How quickly does Angimax start working?

Angimax is generally intended as a long-term management strategy rather than for use during an acute episode. According to official product information, the maximum concentration of the medicine in the blood is typically reached about five hours after administration. The steady state level in the body, which is consistent with sustained use, is generally achieved by the 60th hour of treatment.

Q: Can Angimax be taken long-term?

The medicine is typically prescribed for use over an extended duration, such as weeks or months. Regulatory documents require that the benefit of the treatment be formally re-assessed after a three-month period. Continuation is then contingent upon the re-assessment of the benefit by a healthcare provider.

Q: What are the long-term safety concerns associated with Angimax?

The available evidence indicates that the primary focus of research has been on temporary symptom changes. The research volume addressing long-term effects on major adverse cardiac events, in relation to short-term functional changes, is considered limited. Studies monitored the occurrence of long-term events, but long-term effects on underlying disease progression are not fully established.

Q: How long does Angimax stay in your system?

The time it takes for the body to eliminate half of the medicine (the elimination half-life) is approximately seven hours in young, healthy individuals. Official documents also indicate this time may increase to 12 hours in older adults who are over 65 years old.

Q: Can Angimax affect fertility or be used during pregnancy?

Official regulatory documents state that it is preferable to avoid taking this medicine during pregnancy. Breastfeeding is also not recommended during treatment. This is noted because of a lack of sufficient safety data on the effects during pregnancy and the excretion in breast milk.

Q: Does Angimax affect kidney function?

The medicine is primarily cleared from the body through the kidneys. Regulatory documents require a dose reduction for patients with pre-existing moderate kidney impairment (creatinine clearance 30-60 mL/min). The dose is adjusted because reduced kidney function can lead to increased exposure to the medicine in the body.

Q: Can Angimax be crushed or split?

No. Angimax is a Modified-Release tablet, which is formulated to release the medicine slowly over time. For this reason, official product information states the tablet must be swallowed whole. Crushing, breaking, or chewing is prohibited to maintain the intended release profile.

Q: What kind of monitoring is needed while on Angimax therapy?

Official documents require the benefit of the treatment to be formally re-assessed after a three-month period. Additionally, symptoms related to movement disorders, such as tremor or rigid posture, should be regularly investigated, particularly in elderly patients, as regulatory documents note these symptoms require medical attention.

Q: How is the effectiveness of Angimax measured in studies?

Research studies examine several outcomes to assess the medicine’s effects. These measurements include tracking changes in the frequency of anginal episodes and monitoring patients’ need for short-acting nitrate medication. Studies also evaluate functional capacity, such as the amount of time patients can exercise during standardized stress tests before symptoms begin.

Q: Is Angimax considered a blood pressure medicine?

Angimax is defined as a metabolic modulator, working by changing how heart cells use energy. Studies indicate that it generally has no significant hemodynamic effects. This means that it generally has no effect on heart rate or blood pressure.

Q: Is Angimax the same kind of drug as [Specific similar drug name]?

Angimax (Trimetazidine) belongs to a unique class of medications known as fatty acid oxidation inhibitors. This classification describes its specific action as a metabolic modulator, which differs from other drug classes often used for heart conditions.

Q: Why is Angimax sometimes called a '[Specific drug class]'?

Angimax is sometimes referred to as a fatty acid oxidation inhibitor because its mechanism involves selectively reducing the flux of the Fatty Acid Beta-Oxidation pathway. This action redirects heart cells to prioritize glucose for energy, thereby enhancing the cell's energy efficiency.

Q: Does Angimax make you tired?

Side effects that have been noted in the regulatory profile include sleep disorders. These may manifest as feelings of drowsiness or trouble sleeping. Regulatory documents note that these symptoms require medical attention.

Q: Is Angimax safe for elderly patients?

Official documents note that an increased concentration of the active substance in the body is expected in older adults (over 75 years of age). Official documents indicate caution is noted regarding dosing in this population due to the possibility of increased exposure stemming from age-related changes in kidney function.

Q: Is Angimax a controlled substance?

Regulatory labeling in the United States lists the Drug Enforcement Agency (DEA) schedule as None. This indicates that the medicine is not classified as a controlled substance.

Q: Are there any specific lifestyle changes recommended when taking Angimax?

Official prescribing information defines conditions for use, such as taking the dose during a meal. Beyond this requirement, no other specific mandatory lifestyle changes are listed in the drug's official interaction or administration profile.

Q: What is still uncertain about Angimax research?

The evidence base highlights what remains uncertain. The primary focus of research has been on temporary changes in symptoms rather than on long-term effects on the underlying disease progression. Official documents note that the association between short-term functional improvements and long-term major adverse cardiac events is limited.

Q: Is Angimax safe for people who have had a heart attack?

Official documents state that the medicine is not a treatment for acute myocardial infarction (heart attack). However, clinical studies examining the drug's effectiveness in managing stable angina pectoris have included patients with a history of this condition.

Q: Does Angimax affect blood sugar levels?

The drug is a metabolic modulator that works by promoting glucose oxidation for energy. Research evidence indicates that its action can influence metabolic parameters, with some studies noting effects on blood glucose levels.

How should Angimax be stored and disposed of?

How to Store and Dispose of Angimax

This information details the storage and disposal requirements for Angimax (Nitroglycerin) based on official regulatory labeling.

Official Storage Requirements

Angimax must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The medication must be kept in its original container with the cap screwed on tightly to protect the contents from light and moisture.

Prohibited Environments and Handling

It is essential not to refrigerate or freeze Angimax. The container should not be exposed to excessive heat or humidity. Always ensure the medicine is stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Angimax should be disposed of by following specific guidance. The preferred method is using an authorized drug take-back program. If a program is not available, the medication must be mixed with an undesirable substance (such as used coffee grounds) and placed in a sealed bag before disposal in household trash. It must not be flushed down a toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Angimax found in:

A-Z Index: